Annals of Oncology Advance Access published online on March 8, 2006
Annals of Oncology, doi:10.1093/annonc/mdl027
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medical Oncology, San Raffaele H Scientific Institute, Milan, Italy
* To whom correspondence should be addressed. Background: A pathogenic link between hepatitis C virus (HCV) and MALT-type lymphomas has been suggested. However, studies assessing the role of HCV infection separately in different forms of MALT lymphomas are not available. Patients and methods: The prevalence and clinical implications of HCV seropositivity were analyzed in 55 patients with ocular adnexa lymphoma (OAL) of MALT-type. Results: HCV seropositivity was detected in seven (13%) patients. At presentation, HCV infection was significantly associated with concomitant extra-orbital disease, lymph node dissemination and involvement of additional extranodal organs. HCV seropositivity was associated also with a higher relapse rate and worse progression-free survival. In fact, 16 patients experienced relapse after first-line treatment: five (71%) were HCV-seropositive and 11 (23%) were HCV-seronegative, with a median TTP of 31 and 50+ months (P = 0.01), and a 5-year progression-free survival of 43 ± 18% and 77 ± 7% (P = 0.005), respectively. HCV-seropositive patients experienced frequent relapses despite further lines of therapy; relapses were systemic in all cases but one; multiple subcutaneous nodules were common at relapse. Conclusions: HCV seropositivity is present in 13% of OAL of MALT-type. Concomitant HCV infection is associated with more disseminated disease and aggressive behavior in OAL, with a consequent potential negative impact in patients managed with radiotherapy alone.
Received November 30, 2005
Revised December 16, 2005
Accepted January 20, 2006
original article
Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa
A. J. M. Ferreri 1 *,
E. Viale 2,
M. Guidoboni 3,
A. Giordano Resti 4,
C. De Conciliis 5,
L. Politi 6,
A. A. Lettini 3,
F. Sacchetti 3,
R. Dolcetti 3,
C. Doglioni 7,
and
M. Ponzoni 7
2 Gastroenterology, San Raffaele H Scientific Institute, Milan, Italy
3 Immunovirology and Biotherapy Unit, Department of Pre-Clinical and Epidemiological Research, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy
4 Ophthalmology, San Raffaele H Scientific Institute, Milan, Italy
5 Ophthalmology Unit, Ospedale San Giuseppe, Milan, Italy
6 Neuroradiology, San Raffaele H Scientific Institute, Milan, Italy
7 Pathology Units, San Raffaele H Scientific Institute, Milan, Italy
A. J. M. Ferreri, E-mail: andres.ferreri{at}hsr.it
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Paulli, L. Arcaini, M. Lucioni, E. Boveri, D. Capello, F. Passamonti, M. Merli, S. Rattotti, D. Rossi, R. Riboni, et al. Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT Ann. Onc., October 25, 2009; (2009) mdp454v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy Ann. Onc., May 1, 2008; 19(5): 835 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma Ann. Onc., February 1, 2008; 19(2): 242 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Arnaud, M-C Escande, M Lecuit, P Validire, C Levy, C Plancher, A Vincent-Salomon, N Brousse, P de Cremoux, O Hermine, et al. Hepatitis C virus infection and MALT-type ocular adnexal lymphoma Ann. Onc., February 1, 2007; 18(2): 400 - 401. [Full Text] [PDF] |
||||
![]() |
L Arcaini, S Burcheri, A Rossi, M Paulli, R Bruno, F Passamonti, E Brusamolino, A Molteni, A Pulsoni, M. Cox, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT Ann. Onc., February 1, 2007; 18(2): 346 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferreri, R Dolcetti, P Musto, G. Dognini, C Doglioni, and M Ponzoni Reply to the article 'Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369) Ann. Onc., February 1, 2007; 18(2): 401 - 403. [Full Text] [PDF] |
||||
![]() |
A. J. M. Ferreri, M. Ponzoni, M. Guidoboni, A. G. Resti, L. S. Politi, S. Cortelazzo, J. Demeter, F. Zallio, A. Palmas, G. Muti, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst, October 4, 2006; 98(19): 1375 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options Blood, September 1, 2006; 108(5): 1451 - 1460. [Abstract] [Full Text] [PDF] |
||||


